Primrose Therapeutics
New York
About Primrose Therapeutics
Primrose Therapeutics, Inc. is a biotechnology company focused on the development of treatments for Polycystic Kidney Disease (PKD). PKD is one of the most common life-threatening genetic disorders, affecting 600,000 Americans and 12.5 million people worldwide -- more than cystic fibrosis, muscular dystrophy, hemophilia, Down syndrome and sickle cell anemia combined. PKD results in the abnormal growth of cells in the kidney, which eventually lead to the development of bilateral kidney cysts and structural destruction of the kidney. The average lifespan of PKD patients is 64 years -- at least a decade shorter than average. No FDA approved therapies currently exist for this devastating disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $752.5K
- Funding stage: Seed
- Last round: Seed (Aug 2010)
- Website: primrosetherapeutics.com
- Phone: 212-632-5404
Industries & Categories
Biotechnology, Medical, Therapeutics
Canonical: https://fsome.com/organization/primrose-therapeutics-3307475 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.